Purpose {#sec1}
=======

Soft tissue sarcoma (STS) represents 1% of all adult malignancies and 15% of pediatric ones. In 2016, 12,310 people will be diagnosed with STS in USA \[[@cit0001]\].

Postoperative external beam radiation therapy (EBRT) is considered a standard treatment option. In fact, postoperative EBRT reduces local recurrence rate compared with surgery alone \[[@cit0002],[@cit0003]\]. Furthermore, the use of EBRT achieves the same survival as radical surgery, without the cost of major functional impairment from amputation or extended resection \[[@cit0004]\].

Some of published experiences seems to suggest that the use of a boost with brachytherapy (BRT) can further improve local control rate achievable with adjuvant EBRT \[[@cit0005],[@cit0006],[@cit0007],[@cit0008],[@cit0009],[@cit0010],[@cit0011],[@cit0012]\].

Unfortunately, there is a little evidence in literature on the role of BRT. In fact, most available studies are retrospective and analyze limited number of patients \[[@cit0008],[@cit0013],[@cit0014],[@cit0015],[@cit0016],[@cit0017]\]. Furthermore, these studies included patients with different risk categories (low, intermediate, high). Large series on BRT boost in adjuvant setting are still necessary to define the optimal treatment schedule \[[@cit0018]\]. Therefore, the purpose of this study was to consecutively and homogeneously analyze a large population of patients treated with surgery, followed by adjuvant EBRT and BRT boost.

Material and methods {#sec2}
====================

Study design {#sec2.1}
------------

Medical patients charts, presenting grade 2-3 according to FNLCC (French Fédération Nationale des Centres de Lutte contre le Cancer) system \[[@cit0019]\], primary or recurrent deep STS of extremities or trunk treated with surgery and perioperative BRT followed by adjuvant EBRT ± CHT were retrospectively analyzed. Patients receiving unplanned surgery were excluded.

Patients characteristics {#sec2.2}
------------------------

One hundred and seven patients (median age: 54 years; range: 13-85), treated from January 2000 to January 2011 for high grade primary or recurrent STS were included in this retrospective analysis. Patient and tumor characteristics are shown in [Table 1](#t0001){ref-type="table"}. Median follow-up was 100 months (range: 48-176).

###### 

Patients and treatment characteristics

  Parameter                                     *n*   \%
  --------------------------------------------- ----- ------
  Histology                                           
   Undifferentiated pleomorphic sarcoma (UPS)   27    25.2
   Synovial sarcoma                             20    18.7
   Myxofibrosarcoma                             13    12.1
   Liposarcoma                                  19    17.8
   Leiomyosarcoma                               11    10.3
   Other                                        17    15.9
  Tumor                                               
   Primary                                      44    41.1
   Recurrent                                    63    58.9
  Surgical margins                                    
   Wide                                         72    67.3
   Marginal                                     29    27.1
   Intralesional                                6     5.6
  Gender                                              
   Male                                         56    52.3
   Female                                       51    47.7
  Age (y)                                             
   ≤ 54                                         54    50.5
   \> 54                                        53    49.5
  Site                                                
   Upper limb                                   34    31.8
   Lower limb                                   64    59.8
   Other                                        9     8.4
  pT                                                  
   T1b                                          48    44.9
   T2b                                          59    55.1
  Grade                                               
   2                                            10    9.4
   3                                            97    90.6
  Neoadjuvant chemotherapy                            
   No                                           89    83.2
   Yes                                          18    16.8
  Adjuvant chemotherapy                               
   No                                           82    76.6
   Yes                                          25    23.4

End points {#sec2.3}
----------

The primary end point of the study was to analyze overall survival (OS). Secondary end point was to identify prognostic factors of patients outcome in terms of local control (LC), metastasis-free survival (MFS), and disease-free survival (DFS).

Staging {#sec2.4}
-------

Biopsy was always requested before surgery. Before treatment, all patients underwent chest computed tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), CT, and double contrast enhanced ultrasound of the affected site. The treatment started after histology assessment and staging completion.

Surgery {#sec2.5}
-------

Surgical resection was performed according to the following criteria. The incision was made along the major axis of the tumor-bearing anatomical compartment and included the biopsy track *en bloc*. The quality of surgery was defined by its worst margins and was classified in intralesional, marginal, and wide according to Enneking classification \[[@cit0020]\]. Once the skin fat-flap was prepared, the tumor was isolated within the tumor-bearing structure and removed *en bloc* with the surrounding soft tissue, covered at every point by at least one centimeter of healthy tissue, or less if constituted by an anatomical barrier (fascia or periosteum).

Brachytherapy {#sec2.6}
-------------

At the time of surgical excision, the clinical target volume (CTV) of BRT was defined by surgical, pathological, and imaging findings. Surgical clips were placed at the margins of the tumor bed, and a minimum margin between clips and CTV was used. Placement of the catheters and hollow needles were inserted through the skin and soft tissue parallel or perpendicular to the incision. The distance between the wound incision and the catheter entry point was 1-2 cm. Needles were replaced with BRT catheters with 1-1.5 cm intervals to ensure adequate dosimetry. Catheters could be opened at one or both ends, blind-ended, and terminated with the wound. Once the catheters were in situ with the wound closed, an adequate space (0.5 cm) between the catheter buttons and the skin was ensured for postoperative edema. Dummy ribbons as anatomical landmarks and potential source positions were inserted before a planning CT (sliced obtained at 5 mm intervals) performed 1 week after surgical resection. Catheters were individually numbered. The ribbon reconstruction allowed to identify the basal points where the dose distribution was calculated.

Treatment planning was performed using computer-based optimization algorithms. Once the dosimetry was completed, the prescription dose was delivered to the CTV. The treatment time was determined based on prescribed dose and dose rate. In low-dose-rate (LDR) (2001-2003) and pulsed-dose-rate (PDR) (2004-2011), the median peripheral dose rate, defined as the lowest continuous isodose rate line covering the CTV was identified. This was generally 5 mm from the plane of the implant. The CTV D~60%~, D~80%~, D~100%~, D~120%~, D~140%~, D~160%~ (the minimum dose to 60-160%) of the CTV were always reported. Once the treatment planning was calculated and the dose distribution was evaluated and accepted, the catheters were connected to a projection sources of Iridium-192 and the dose was delivered through the automatic loading of miniaturized sources.

The delivered dose was 20 Gy at dose-rate of 0.30-0.80 Gy/hour, and 0.80 Gy/pulse for LDR and PDR, respectively. The treatment lasted 24-30 hours and 24 hours for LDR and PDR, respectively. A hospitalization for 1-2 day was necessary. Once the treatment was completed, the catheters were removed.

External beam radiation therapy {#sec2.7}
-------------------------------

Simulation was generally performed 3-4 weeks after surgical resection, 2-3 weeks after brachytherapy treatment. Patients were immobilized in supine or prone position with different immobilization devices, such as vacuum cushions, cradle devices, feetstep (feet support cushion), or kneestep (knee support cushions). Planning CT slices for each patient were obtained at 5-mm intervals, including the surgical wound with adequate margins.

Patients underwent a pre-operative MRI-scan, which was co-registered, if possible, with the planning CT scan for delineation of target volumes and normal tissues including the organs at risk (OAR). The CTV was identified by planning CT and preoperative MRI, and was defined as the tumor and surgical bed, including the scar and the drainage site, adding 3 cm longitudinally and 1 cm radially. These margins were reduced at surfaces of fascia and bones, unless invaded.

CTV was expanded into planning target volume (PTV) by adding an isotropic 1-cm margin to account for uncertainties setup. Also OAR (bones, joints, testicles, bladder, rectum, intestine for low extremities STS; bones and lung for upper extremities STS) were delineated. 3D conformal radiotherapy plans were generated with the requirement that at least 95% of the PTV should receive 95% of the prescribed dose. To prevent lymphedema, a "soft tissue strip/corridor" was identified to avoid irradiation of the extremities entire circumference. Isodose distributions in three planes (axial, sagittal, coronal) and cumulative dose-volume histograms of PTV and OAR were used to guide plan optimization.

The prescribed dose was 46 Gy to the PTV, delivered over 23 daily fractions (2 Gy/fraction). A multiple beams technique was used in order to achieve the best PTV coverage, while reducing irradiation of OARs and avoiding irradiation of contralateral limb (in case of lower limbs STS). All patients were treated with 6-18 MV X-rays from linear accelerators equipped with multileaf collimators with 1-cm leaf width at the isocenter. To ensure the correct positioning, patient setup was checked at least on a weekly basis by using electronic portal images device. Deviations \> 5 mm were immediately corrected. External beam radiation therapy started within 90 days after surgery.

Chemotherapy {#sec2.8}
------------

Neoadjuvant and adjuvant chemotherapy (CHT) consisted of epirubicin (60 mg/m^2^/day, short infusion, days 1-2) and ifosfamide (3 g/m^2^/day, days 1-2-3) were prescribed to those patients with potentially chemosensitive histological subtypes. The number of CHT cycles ranged between 3 and 5. In case of neoadjuvant chemotherapy, surgery was performed at the end of the last cycle, after recovery from hematological toxicity and instrumental restaging. External beam radiation therapy was performed at the end of adjuvant CHT after the recovery from bone marrow toxicity. In the interval periods, prophylactic use of granulocyte colony-stimulating factor (G-CSF) was recommended. The interval between adjuvant CHT and EBRT was assessed case by case, depending on the hematological toxicity manifested by each individual patient.

Dose modifications {#sec2.9}
------------------

According to hematological toxicity, the following recommendations for dose adjustment were provided. Grade 0-1 toxicity did not require CHT dose reductions. If grade 2 toxicity was registered, a 25% CHT dose reduction was recommended and G-CSF were prescribed. In case of grade 3-4 toxicity, CHT was interrupted until recovery of toxicity to the grade ≤ 2. External beam radiation therapy was interrupted only in case of grade 3-4 toxicity, until recovery of toxicity to grade ≤ 2.

Follow-up {#sec2.10}
---------

Patients were evaluated 3 weeks after RT or CHT completion, every 3 months thereafter for the first 2 years, then every 6 months for the first 5 years, and later annually. Patients evaluation included history and physical examination, blood tests of metabolic panel and hematological profile, ECOG status, and toxicity assessment. Chest CT and a contrast-enhanced MRI, CT, and double contrast enhanced ultrasound of the affected site were performed 3 months after the treatment and every 6 months for the first 5 years.

Statistical analysis {#sec2.11}
--------------------

Statistical analysis was performed using SYSTAT, version 11.0 (SPSS, Chicago, IL). Univariate analyses were performed to evaluate individual risk factors. For each variables category, LC, MFS, DFS, and OS were estimated according to the Kaplan-Meier method, and the log-rank test was used to compare survival curves. Multivariable analysis was not conducted when investigating local control or death due to the limited number of events (19 and 13, respectively). For disease-free survival, multivariable analysis were not conducted because only one predictor (namely, site), reached the statistical significance threshold (*p* \< 0.10) established a priori. When studying metastases-free survival, there was no predictor reaching the statistical threshold.

The differences were considered statistically significant if the *p*-value was \< 0.05.

Results {#sec3}
=======

Patients outcome {#sec3.1}
----------------

1-year and 3-year LC were 96.2% and 86.3%, respectively. Overall, 5-year LC was 80.9%: 90.9% for primary STS and 74.2% for recurrent tumor. Three-year and 5-year MFS, DFS, and OS were 76.9%, 69.4%, 95.1%, and 69.8%, 58.6%, 87.4%, respectively. Overall, during follow-up, 19 patients developed local recurrence, 30 patients distant metastases, 42 patients relapse events, and 13 patients died.

Univariate analysis {#sec3.2}
-------------------

[Table 2](#t0002){ref-type="table"} shows the results of the univariate analysis. A higher LC rate was recorded in patients treated for primary sarcomas compared to recurrent tumors. Patients with lower limbs STS showed a better 5-year LC compared to upper limbs or trunk sarcomas. A trend between LC and margin status was also recorded with higher LC rate in patients with wide surgical margins. The other analyzed parameters did not show a significant correlation or trend with LC. Disease-free survival was significantly correlated to the disease site: 5-year DFS was 71.0% for lower limbs, and 38.4% and 41.7% for upper-limb and trunk tumors, respectively ([Figure 1](#f0001){ref-type="fig"}). A trend was observed between histology and OS (*p* = 0.069) with myxofibrosarcoma and liposarcoma showing a better survival. Leiomyosarcoma showed a high LC rate (5-year LC, 90.9%) while showing a relatively poor outcome in terms of OS (5-year OS, 72.7%).

![Actuarial disease-free survival correlated to the disease site](JCB-9-30089-g001){#f0001}

###### 

Univariate analysis (5-year results)

  Parameter           Nr Pts   Local control   *p*     Metastases-free survival   *p*     Disease-free survival   *p*     Overall survival   *p*
  ------------------- -------- --------------- ------- -------------------------- ------- ----------------------- ------- ------------------ -------
  Group                                                                                                                                      
   Primary            44       90.9            0.015   63.4                       0.123   60.2                    0.848   95.2               0.342
   Recurrent          63       74.2            74.2    57.6                       82.6                                                       
  Histology                                                                                                                                  
   UPS                27       95.8            0.125   62.4                       0.284   62.4                    0.895   82.9               0.069
   Synovial sarcoma   20       85.0            67.8    58.3                       82.1                                                       
   Myxofibrosarcoma   13       68.4            83.9    60.6                       100.0                                                      
   Liposarcoma        19       71.9            81.2    53.8                       100.0                                                      
   Leiomyosarcoma     11       90.9            63.6    63.6                       72.7                                                       
   Other              17       68.4            64.9    55.4                       90.9                                                       
  Margins                                                                                                                                    
   Wide               72       86.1            0.075   73.6                       0.626   63.3                    0.369   91.6               0.259
   Marginal           29       70.5            61.0    48.2                       77.9                                                       
   Intralesional      6        66.7            67.7    50.0                       83.3                                                       
  Gender                                                                                                                                     
   Male               56       83.0            0.392   71.3                       0.755   59.3                    0.864   86.7               0.858
   Female             51       78.5            68.4    58.0                       88.2                                                       
  Age                                                                                                                                        
   ≤ 54               54       79.5            0.700   68.1                       0.814   56.2                    0.800   91.2               0.196
   \> 54              53       82.7            72.3    62.0                       82.8                                                       
  Site                                                                                                                                       
   Upper limb         34       64.7            0.027   61.5                       0.370   38.4                    0.034   77.9               0.422
   Lower limb         64       90.1            75.8    71.0                       89.8                                                       
   Trunk              9        74.1            55.6    41.7                       100.0                                                      
  Grade                                                                                                                                      
   2                  10       67.5            0.203   88.9                       0.202   56.3                    0.980   83.3               0.794
   3                  97       82.2            67.9    58.7                       87.6                                                       
  pT                                                                                                                                         
   T1b                48       76.9            0.420   75.8                       0.115   62.2                    0.283   81.6               0.195
   T2b                59       84.3            65.3    56.0                       92.4                                                       
  Stage                                                                                                                                      
   II                 49       75.3            0.196   76.2                       0.092   60.9                    0.421   81.7               0.201
   III                58       85.8            64.8    57.0                       92.3                                                       
  CT Pre                                                                                                                                     
   No                 89       81.5            0.361   69.7                       0.960   58.2                    0.656   88.6               0.245
   Yes                18       76.9            70.5    60.6                       81.0                                                       
  CT Post                                                                                                                                    
   No                 82       78.8            0.389   74.3                       0.147   60.7                    0.575   89.4               0.244
   Yes                25       87.8            54.9    52.1                       81.3                                                       

CT -- chemotherapy, UPS -- undifferentiated pleomorphic sarcoma

Discussion {#sec4}
==========

Our study was performed in order to assess the impact of adjuvant EBRT and anticipated BRT boost on LC in patients with STS. To the best of our knowledge, it is the largest series on adjuvant EBRT plus BRT boost in STS.

This study has the limitation of a retrospective assessment, variable use of chemotherapy, and absence of data on acute and late toxicities. Moreover, patients recruitment took place over a long period of time (10 years). This could have reduced the homogeneity in patients management due to evolution of staging and treatment techniques. Furthermore, data about treatment interruption or delay are missing. However, all patients were followed by the same team of radiologists, radiation oncologists, surgeons, and medical oncologists and all patients underwent the same type of combined treatment (BRT + EBRT) with uniform doses.

We should admit that preoperative RT is able to reduce late morbidity compared to postoperative RT \[[@cit0021]\], and that BRT has very limited role in STS in the present intensity modulated RT era. However, being postoperative RT still used in several centers, we presented our large series of patients with prolonged follow-up. In our study, as expected, a correlation was observed between tumor type (primary vs. recurrent) and LC (90.9% vs. 74.2%; *p* = 0.015), without a significant impact on MFS, DFS, and OS. The same significant correlation between tumor type and LC was found in other publications. Petera *et al.* \[[@cit0012]\] examined the results of 34 patients with STS, treated between 1998 and 2007 with HDR-BRT (mean dose 24 Gy; 15-30 Gy) and EBRT (40-50 Gy), showing that LC was 100% in primary tumors and 64% in recurrent lesions (*p* = 0.004). They observed a tendency toward more local recurrences in patients with a close/positive margin than in patients with a negative margin. Also in our study, a statistical trend was found with 5-year LC of 86.1%, 70.5%, and 66.7% in patients with wide, marginal, and intralesional margins, respectively.

Another significant correlation recorded in our analysis was between tumor site (lower limb vs. upper limb and trunk), and LC and DFS. The worse results recorded in upper limb STS may depend on the greater difficulty of radical surgery in this dimensionally smaller and richer of neurovascular bundles area.

[Table 3](#t0003){ref-type="table"} shows the results of the comparison between other studies \[[@cit0007],[@cit0012],[@cit0013],[@cit0014],[@cit0018],[@cit0022]\] and our results. Local control and OS were similar to that recorded in other centers despite inclusion of intermediate-high grade (HG) STS only. On the contrary, in other published studies, the analyzed populations also included low grade (LG) STS, generally showing a better prognosis \[[@cit0007],[@cit0012],[@cit0013],[@cit0014],[@cit0018],[@cit0022]\]. The favorable impact of adjuvant radiation therapy on LC compared to surgery alone has been shown in several studies \[[@cit0007],[@cit0012],[@cit0013],[@cit0014],[@cit0018],[@cit0022]\]. However, it is more difficult to define the role of BRT boost. In fact, only Andrews *et al*. \[[@cit0018]\] analyzed the difference in terms of LC and OS between patients treated with perioperative BRT followed by EBRT or EBRT alone, and reported an improved LC and OS in patients receiving a combined treatment. We can observe that several studies reporting on surgery plus postoperative EBRT recorded 5-year LC rates (75.5-87.0%) similar to our series, where BRT boost was used (80.9%). Nevertheless, we should stress again that some of these studies included even patients with low-grade disease \[[@cit0003],[@cit0023],[@cit0024],[@cit0025],[@cit0026],[@cit0027]\]. Furthermore, two of these trials involved only patients with primary tumors \[[@cit0003],[@cit0024]\].

###### 

Literature results

  Authors (reference)                            Center                                               Median follow-up   Inclusion criteria                                                                      No. of patients   EBRT dose (Gy)                              BRT dose (Gy)                                                           Chemotherapy   5-year local control                                                    5-year overall survival
  ---------------------------------------------- ---------------------------------------------------- ------------------ --------------------------------------------------------------------------------------- ----------------- ------------------------------------------- ----------------------------------------------------------------------- -------------- ----------------------------------------------------------------------- -------------------------
  Petera *et al.*, 2010 \[[@cit0012]\]           University Hospital Hradek Kralovè, Czech Republic   38.4 (3.6-114)     Primary (17) + recurrent (28); Low risk (20); Intermediate/high risk (25)               45                40-50                                       HDR (30-54; median: 40) in 11 pts. HDR (15-30; median: 24) in 34 pts.   +/−            74%                                                                     70%
  Martinez-Monge *et al.,* 2005 \[[@cit0014]\]   University of Navarra, Pamplona, Spain               23.2 (2.8-48)      Primary (24) + recurrent (1); Low risk (9); Intermediate/high risk (16)                 25                45                                          HDR 16-32                                                               +/−            4-year: 100% local 80.5% regional                                       4-year: 78.2%
  Itami *et al.* 2010 \[[@cit0013]\]             National Cancer Central Hospital, Tokyo, Japan       49.7               Primary (12) + recurrent (14); Margins +/−; Low risk (2); Intermediate/high risk (24)   26                --                                          HDR 36                                                                  +/−            78.2% (43.8% recurrent + pos. margins; 93.3% primitive, neg. margins)   75.6%
  Lazzaro *et al*., 2005 \[[@cit0007]\]          IEO, Milano, Italy                                   34 (12-56)         Primary (32) + recurrent (10); Low risk (7) + intermediate/high risk (35)               42                50 (40-66) in 24 pts                        PDR (45-60; median: 45) in 18 pts. PDR (10-29; median: 15) in 24 pts.   +/−            3-year: 89%                                                             3-year: 83.9%
  Andrews *et al.*, 2004 \[[@cit0018]\]          Fox Chase Cancer Center, Philadelphia, USA           62                 Low risk (24); Intermediate/high risk (48); Unknown (14)                                86                50 (40-70) in 25 pts 59 (50-74) in 61 pts   LDR (10-20; median: 16) in 25 pts.                                      +/−            90% 83%                                                                 82% 72%
  San Miguel *et al.*, 2011 \[[@cit0022]\]       Clınica Universidad de Navarra, Spain                49.3 (5.9-107)     Primary (50) + recurrent (10); Low risk (16); Intermediate/high risk (44)               60                45                                          HDR (16-24)                                                             +/−            9-year: 77.4%                                                           9-year: 61.5%
  Present series                                 Bologna, University, Italy                           100 (48-176)       Primary (44) + recurrent (63); Intermediate/high risk (107)                             107               46                                          LDR/PDR (20)                                                            +/−            80.9%                                                                   87.4%

EBRT -- external beam radiation therapy, BRT -- brachytherapy, HDR -- high-dose-rate, LDR -- low-dose-rate, PDR -- pulsed-dose rate

Conclusions {#sec5}
===========

In conclusion, the results of this analysis show that a combination of BRT and EBRT is able to produce high LC and OS rates even in a patients population with intermediate-high risk STS. Therefore, this type of treatment could be proposed in patients with the same disease characteristics in combination with CHT in tumors with chemosensitive tumors.

Prospective studies on the use of BRT/EBRT with uniform radiation doses and large patient population in the adjuvant setting of STS are still needed to define the optimal treatment schedule. Particularly, based on our results, treatment intensification should be tested in patients with unfavorable prognostic factors (recurrent tumors and other than lower limb sites).
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